Search Results - "Nataša Smrekar"

Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn’s Disease Likely to Achieve Endoscopic and Biochemical Remission by Hanžel, Jurij, Zdovc, Jurij, Kurent, Tina, Sever, Nejc, Javornik, Katarina, Tuta, Katja, Koželj, Matic, Smrekar, Nataša, Novak, Gregor, Štabuc, Borut, Dreesen, Erwin, Thomas, Debby, Vovk, Tomaž, Grabnar, Iztok, Drobne, David

“…Little is known about the relationship between ustekinumab exposure during the first 2 weeks of treatment and outcomes of patients with Crohn’s disease (CD)…”
Get full text

Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease by Drobne, David, Kurent, Tina, Golob, Saša, Švegl, Polona, Rajar, Polona, Hanžel, Jurij, Koželj, Matic, Novak, Gregor, Smrekar, Nataša, Ferkolj, Ivan, Štabuc, Borut

“…Summary Background Combination treatment with azathioprine for 6‐12 months is the preferred strategy for starting infliximab due to improved pharmacokinetics…”
Get full text

Biopsies from ulcer edge yield higher histological activity scores than biopsies from non-ulcerated mucosa in active ulcerative colitis by Novak, Gregor, Sever, Nejc, Hanžel, Jurij, Koželj, Matic, Kurent, Tina, Smrekar, Nataša, Drobne, David, Zidar, Nina

“…The appropriate location for biopsy collection in ulcerative colitis is unknown. We aimed to determine the location for biopsy collection in the presence of…”
Get full text

Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease by Pintar, Špela, Hanžel, Jurij, Drobne, David, Koželj, Matic, Kurent, Tina, Smrekar, Nataša, Novak, Gregor

“…: The subcutaneous (SC) formulation of vedolizumab has proven to be effective for the maintenance of remission after intravenous induction. Little is known…”
Get full text

Ustekinumab concentrations shortly after escalation to monthly dosing may identify endoscopic remission in refractory Crohn’s disease by Hanžel, Jurij, Koželj, Matic, Špes Hlastec, Ana, Kurent, Tina, Sever, Nejc, Zdovc, Jurij, Smrekar, Nataša, Novak, Gregor, Štabuc, Borut, Grabnar, Iztok, Drobne, David

“…Some patients with Crohn's disease do not achieve remission with the approved maintenance dosing of ustekinumab every 8 weeks, possibly due to insufficient…”
Get full text

IgA Nephropathy in a Patient Treated with Adalimumab by Mertelj, Tonja, Smrekar, Nataša, Kojc, Nika, Lindič, Jelka, Kovač, Damjan

“…Abstract Immunoglobulin A (IgA) nephropathy (IgAN) is the most common glomerulonephritis worldwide, characterized by IgA deposits in the glomerular mesangium…”
Get full text

Biological treatment approach to inflammatory bowel disease is similar in academic and nonacademic centres - prime time for decentralisation of inflammatory bowel disease care? by Tepeš, Katja, Hanžel, Jurij, Štubljar, David, Strmšek, Karin, Erjavec, Luka, Supovec, Eva, Jagodic, Zala, Končan, Mirjam, Grosek, Jan, Košir, Jurij Aleš, Tomažič, Aleš, Kogovšek, Urška, Norčič, Gregor, Šibli, Renata, Žnidaršič, Marija, Pačnik Vižintin, Tadeja, Sodin, Barbara, Breznik, Janez, Hribar, Vanesa Anderle, Ocepek, Andreja, Pernat Drobež, Cvetka, Bukovnik, Nejc, Zafošnik, Andrej, Marušič, Tamara, Jurečič Brglez, Nataša, Denkovski, Maja, Smrekar, Nataša, Novak, Gregor, Koželj, Matic, Kurent, Tina, Simonič, Jože, Pintar, Špela, Štabuc, Borut, Drobne, David

“…With the increasing number of inflammatory bowel disease (IBD) patients, it is difficult to manage them within specialised IBD teams in academic medical…”
Get full text

Comparison of radon doses based on different radon monitoring approaches by Vaupotič, Janja, Smrekar, Nataša, Žunić, Zora S.

“…In 43 places (23 schools, 3 kindergartens, 16 offices and one dwelling), indoor radon has been monitored as an intercomparison experiment, using…”
Get full text

Insights into treatment of complex Crohn's perianal fistulas by Norčič, Gregor, Smrekar, Nataša, Marković, Srđan, Barišić, Goran, Kiudelis, Gediminas, Paužas, Henrikas, Molnár, Tamás, Szijarto, Attila, Šerclová, Zuzana, Roblek, Tina, Uršič, Viktor, White, Ian

“…Complex perianal fistula is a common complication of Crohn's disease (CD) which leads to negative impact on patient's quality of life. Successful management of…”
Get full text

Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease by Hanžel, Jurij, Sever, Nejc, Ferkolj, Ivan, Štabuc, Borut, Smrekar, Nataša, Kurent, Tina, Koželj, Matic, Novak, Gregor, Compernolle, Griet, Tops, Sophie, Gils, Ann, Drobne, David

“…Background The relationship between vedolizumab trough levels and combined endoscopic and clinical remission is unknown. Objective To compare vedolizumab…”
Get full text

Success and safety of high infliximab trough levels in inflammatory bowel disease by Drobne, David, Kurent, Tina, Golob, Sasa, Svegl, Polona, Rajar, Polona, Terzic, Sara, Kozelj, Matic, Novak, Gregor, Smrekar, Natasa, Plut, Samo, Sever, Nejc, Strnisa, Luka, Hanzel, Jurij, Brecelj, Jernej, Urlep, Darja, Osredkar, Josko, Homan, Matjaz, Orel, Rok, Stabuc, Borut, Ferkolj, Ivan, Smid, Alojz

“…Objective: A prospective trial suggests target infliximab trough levels of 3-7 μg/mL, yet data on additional therapeutic benefits and safety of higher trough…”
Get full text

Ustekinumab Dosing Individualization in Crohn’s Disease Guided by a Population Pharmacokinetic–Pharmacodynamic Model by Aguiar Zdovc, Jurij, Hanžel, Jurij, Kurent, Tina, Sever, Nejc, Koželj, Matic, Smrekar, Nataša, Novak, Gregor, Štabuc, Borut, Dreesen, Erwin, Thomas, Debby, Vovk, Tomaž, Ostanek, Barbara, Drobne, David, Grabnar, Iztok

“…Ustekinumab is a monoclonal antibody used in Crohn’s disease (CD). Dose optimization in case of non-response and the role of pharmacokinetic–pharmacodynamic…”
Get full text

Biopsies from ulcer edge yield higher histological activity scores than biopsies from non-ulcerated mucosa in active ulcerative colitis by Novak, Gregor, Sever, Nejc, Hanžel, Jurij, Koželj, Matic, Kurent, Tina, Smrekar, Nataša, Drobne, David, Zidar, Nina

Get full text

Dendritic cell profiles in the inflamed colonic mucosa predict the responses to tumor necrosis factor alpha inhibitors in inflammatory bowel disease by Smrekar, Natasa, Drobne, David, Smid, Lojze M., Ferkolj, Ivan, Stabuc, Borut, Ihan, Alojz, Kopitar, Andreja Natasa

“…Background Dendritic cells play crucial roles in the control of inflammation and immune tolerance in the gut. We aimed to investigate the effects of tumor…”
Get full text

Ustekinumab concentrations shortly after escalation to monthly dosing may identify endoscopic remission in refractory Crohn’s disease by Hanžel, Jurij, Koželj, Matic, Špes Hlastec, Ana, Kurent, Tina, Sever, Nejc, Zdovc, Jurij, Smrekar, Nataša, Novak, Gregor, Štabuc, Borut, Grabnar, Iztok, Drobne, David

Get full text

Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label by Stefanovic, Sebastian, Detrez, Iris, Compernolle, Griet, Brouwers, Els, Sever, Nejc, Stabuc, Borut, Smrekar, Natasa, Kurent, Tina, Novak, Gregor, Kozelj, Matic, Ferrante, Marc, Gils, Ann, Drobne, David

“…BACKGROUNDIn 2018, the European Medicines Agency (EMA) replaced a fixed 50 mg every 4-week maintenance regimen of golimumab for ulcerative colitis (UC)…”
Get full text

Slovenska priporočila za obravnavo odraslih bolnikov s kronično odpovedjo prebavil by Nada Rotovnik Kozjek, Tajda Košir Božič, Katja Kogovšek, Borut Štabuc, Laura Petrica, Karla Berlec, Nataša Ravnjak Puzič, Erik Brecelj, Aleš Tomažič, Sanela Banovič, Rada Franko, Milena Blaž Kovač, Janez Breznik, Davorin Ćeranić, David Drobne, Mojca Gašperin, Tomaž Jurca, Maja Ebert Moltara, Rado Janša, Marjana Turk Jerovšek, Taja Jordan, Tina Kamhi Trop, Primož Karner, Milena Kerin, Neža Majdič, Denis Mlakar Mastnak, Andreja Ocepek, Tadeja Pintar, Stojan Potrč, Nataša Smrekar, Monika Sonc, Maja Šeruga, Petra Tavčar, Igor Virant

“…Slovenska priporočila za obravnavo bolnikov z kronično odpovedjo prebavil so povzeta so po smernicah Evropskega združenja za klinično prehrano in metabolizem…”
Get full text

Mo1836 - Vedolizumab Trough Levels at Week 6 Predict Endoscopic and Clinical Remission in Inflammatory Bowel Disease by Hanzel, Jurij, Sever, Nejc, Ferkolj, Ivan, Stabuc, Borut, Smrekar, Natasa, Kozelj, Matic, Novak, Gregor, Gils, Ann, Drobne, David

Get full text

Golimumab Trough Levels Predict Mucosal Healing and Success of Dose Optimization: A Prospective Observational Study: 737 by Stefanovic, Sebastian, Detrez, Iris, Compernolle, Griet, Brouwers, Els, Sever, Nejc, Stabuc, Borut, Ferkolj, Ivo, Smrekar, Natasa, Kurent, Tina, Novak, Gregor, Kozelj, Matic, Ferrante, Marc, Gils, Ann, Drobne, David

“…Introduction: Real-life data on clinical efficacy and pharmacokinetics of golimumab in ulcerative colitis are scarce. Methods: We studied correlation of…”
Get full text

IgA Nephropathy in a Patient Treated with Adalimumab by Mertelj, Tonja, Smrekar, Nataša, Kojc, Nika, Lindič, Jelka, Kovač, Damjan

Get full text